The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

SHANGHAI, Sept. 20, 2023 /PRNewswire/ — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has announced that the…